Heron Therapeutics, Inc. — FY2019 Form 10-K Summary
Business context and reporting period
Heron Therapeutics is a commercial-stage biotechnology company developing drug-delivery products for cancer supportive care and postoperative pain. This filing covers the fiscal year ended December 31, 2019, and was filed March 2, 2020.
- Commercial products: CINVANTI, an intravenous aprepitant formulation for prevention of chemotherapy-induced nausea and vomiting, and SUSTOL, an extended-release granisetron injection.
- Pipeline: HTX-011, an investigational extended-release bupivacaine/meloxicam product for postoperative pain, and HTX-034, an earlier-stage postoperative pain candidate.
- Reporting basis: Product revenue is recognized when sold to specialty distributors under ASC 606 and is reduced by returns, discounts, rebates, distributor fees and other allowances.
Key financial metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Net product sales | $146.0 million | $77.5 million | +88.4% |
| Cost of product sales | $61.6 million | $27.5 million | +124.0% |
| Gross profit | $84.3 million | $50.0 million | +68.7% |
| Gross margin | 57.8% | 64.5% | Down 6.7 percentage points |
| Research and development | $167.4 million | $140.0 million | +19.5% |
| General and administrative | $37.9 million | $29.3 million | +29.5% |
| Sales and marketing | $89.8 million | $64.6 million | +39.0% |
| Loss from operations | $(210.7) million | $(183.9) million | Loss increased |
| Net loss | $(204.7) million | $(178.8) million | Loss increased 14.5% |
| Net loss per share | $(2.50) | $(2.44) | Higher loss per share |
| Net cash used in operations | $(124.6) million | $(191.8) million | Cash use decreased |
Calculated operating margin was approximately (144.3%) in 2019 versus (237.4%) in 2018; net margin was approximately (140.3%) versus (230.8%). Despite improved revenue leverage, the company remained significantly unprofitable.
- Product mix: CINVANTI sales were $132.2 million, up from $56.2 million. SUSTOL sales were $13.8 million, down from $21.3 million.
- Liquidity: Cash, cash equivalents and short-term investments totaled $391.0 million at year-end, including $71.9 million of cash and cash equivalents and $319.1 million of short-term investments. Working capital was $382.4 million.
- Cash flows: Investing cash use was $21.8 million, while financing provided $186.4 million, primarily from a $162.2 million net common-stock offering.
- Debt: Convertible notes had $7.2 million of principal outstanding and a $5.6 million carrying value. The notes bear 6% interest, mature in 2021, are secured by substantially all assets and are convertible into approximately 9.0 million shares.
- Potential dilution: Conversion of the notes would represent approximately 9.0% of outstanding shares after conversion, according to the filing.
- Accumulated deficit: $1.17 billion at December 31, 2019.
Material changes versus the prior comparable period
- CINVANTI growth drove the increase in total sales, supported by its January 2019 J-code becoming effective and the February 2019 approval of a two-minute IV injection option.
- FDA approval in October 2019 expanded CINVANTI’s label and recommended dosage to include a 130 mg single-dose regimen for MEC.
- SUSTOL sales declined, reflecting generic competition and the October 2019 decision to discontinue all SUSTOL discounting, which management stated would result in significantly lower future net sales.
- Gross margin declined because cost of product sales grew faster than revenue; cost of sales included a $3.3 million write-off of short-dated SUSTOL inventory, compared with $1.8 million in 2018.
- R&D increased primarily because of HTX-011 and HTX-034 development, higher personnel costs and stock-based compensation. HTX-011-related R&D costs were $95.3 million.
- Sales and marketing increased to prepare for a potential HTX-011 launch and included $8.4 million of stock-based compensation related to modifications following the President’s retirement.
- The company raised $162.2 million net through an October 2019 common-stock offering, increasing issued and outstanding shares to 90.3 million at year-end from 78.2 million.
- Adoption of ASC 842 resulted in recognition of $13.8 million of right-of-use lease assets and $14.2 million of lease liabilities at year-end; management reported no material impact on operations or liquidity.
Guidance, outlook, risks and unusual items
- Management expected R&D expense to increase significantly in 2020 for HTX-011, HTX-034, clinical and manufacturing activities, and postmarketing requirements for CINVANTI and SUSTOL.
- Management expected sales and marketing expense to increase significantly in 2020 to support a potential HTX-011 launch, while G&A expense was expected to remain consistent with 2019.
- Management stated that existing liquidity was sufficient to fund anticipated requirements for at least one year from the filing date, but acknowledged that additional capital may be needed and may not be available on favorable terms.
- HTX-011 received an FDA Complete Response Letter on April 30, 2019 requesting additional chemistry, manufacturing and controls and non-clinical information. The company resubmitted the NDA in September 2019; the PDUFA goal date was June 26, 2020. The filing states that no clinical efficacy or safety issues were identified in the CRL.
- The HTX-011 contract manufacturing site was reinspected without Form 483 observations, but final approval remained uncertain. The company relied on third-party manufacturers, with some critical components sourced from single suppliers.
- HTX-011 applications were under review in Europe and Canada, with decisions anticipated in 2020. These regulatory timelines and outcomes were not assured.
- Competition increased materially: generic EMEND IV entered in September 2019, increasing pressure on CINVANTI, while generic ALOXI competition had already reduced SUSTOL sales.
- Contractual obligations totaled $94.4 million at year-end, including $65.8 million of purchase obligations and $11.1 million of capital expenditure commitments. Clinical trial obligations were variable and not included in that total.
- Revenue recognition depends substantially on estimates for product returns and other allowances. Product sales allowances recorded during 2019 were $162.2 million, with a year-end accrued balance of $27.9 million.
- The company reported no material legal proceedings, an unqualified financial statement audit opinion and an unqualified opinion on internal control over financial reporting.
Most important facts for investors to verify
- Whether HTX-011 obtained FDA approval by the June 26, 2020 PDUFA date and whether launch timing and launch costs differed from management’s expectations.
- Whether CINVANTI growth offset continuing SUSTOL erosion from generic competition and the elimination of SUSTOL discounts.
- The sustainability of the reported 57.8% gross margin after inventory write-offs, rebates, distributor allowances and further competitive pricing pressure.
- Cash burn, financing needs and covenant or prepayment risks associated with the secured convertible notes.
- The potential dilution from approximately 9.0 million shares issuable on conversion of the notes, as well as outstanding options and warrants.
- Actual product returns and rebate experience relative to the $27.9 million accrued product-sales allowance and the company’s significant reliance on three distributors, which represented 97.8% of 2019 sales.
- Manufacturing capacity, single-source supply exposure and the ability of third-party manufacturers to support commercial-scale HTX-011 production.
- The company’s ability to achieve profitability given its $1.17 billion accumulated deficit, continuing operating losses and planned increases in development and commercialization spending.